VaxSyna INC.


VaxSyna, Inc. is a pre-clinical vaccine R&D company developing an antibody-based vaccine platform. Our vaccine platform can be utilized to create both prophylactic and therapeutic vaccines and is 1) up to 50% cheaper to manufacture compared to other vaccines, 2) stable at room temperature in preliminary studies, 3) generates a protective immune response in 1-2 doses without the use of expensive adjuvants and 4) effective in multiple pre-clinical trials against various diseases. VaxSyna’s two primary vaccine candidates are against Human Papillomavirus (HPV) and Herpes Simplex Virus (HSV).